nodes	percent_of_prediction	percent_of_DWPC	metapath
Nedocromil—HSP90AA1—breast cancer	0.655	1	CbGaD
Nedocromil—CYSLTR2—female reproductive system—breast cancer	0.00399	0.0706	CbGeAlD
Nedocromil—PTGDR—adipose tissue—breast cancer	0.00369	0.0653	CbGeAlD
Nedocromil—FPR1—bone marrow—breast cancer	0.00339	0.06	CbGeAlD
Nedocromil—PTGDR—adrenal gland—breast cancer	0.00331	0.0586	CbGeAlD
Nedocromil—PTGDR—bone marrow—breast cancer	0.00321	0.0567	CbGeAlD
Nedocromil—HSP90AA1—mammary gland—breast cancer	0.00315	0.0558	CbGeAlD
Nedocromil—FPR1—endocrine gland—breast cancer	0.00304	0.0538	CbGeAlD
Nedocromil—HSP90AA1—nipple—breast cancer	0.00261	0.0461	CbGeAlD
Nedocromil—HSP90AA1—embryo—breast cancer	0.00215	0.038	CbGeAlD
Nedocromil—PTGDR—lymph node—breast cancer	0.00199	0.0351	CbGeAlD
Nedocromil—HSP90AA1—epithelium—breast cancer	0.00176	0.031	CbGeAlD
Nedocromil—CYSLTR1—uterus—breast cancer	0.00167	0.0296	CbGeAlD
Nedocromil—HSP90AA1—skin of body—breast cancer	0.00167	0.0295	CbGeAlD
Nedocromil—CYSLTR1—adipose tissue—breast cancer	0.00164	0.0289	CbGeAlD
Nedocromil—HSP90AA1—endometrium—breast cancer	0.00157	0.0278	CbGeAlD
Nedocromil—CYSLTR1—female reproductive system—breast cancer	0.0015	0.0266	CbGeAlD
Nedocromil—CYSLTR1—adrenal gland—breast cancer	0.00147	0.0259	CbGeAlD
Nedocromil—HSP90AA1—uterus—breast cancer	0.00145	0.0257	CbGeAlD
Nedocromil—HSP90AA1—pituitary gland—breast cancer	0.00142	0.0252	CbGeAlD
Nedocromil—CYSLTR1—bone marrow—breast cancer	0.00142	0.0251	CbGeAlD
Nedocromil—HSP90AA1—adipose tissue—breast cancer	0.00142	0.0251	CbGeAlD
Nedocromil—HSP90AA1—female reproductive system—breast cancer	0.0013	0.0231	CbGeAlD
Nedocromil—HSP90AA1—adrenal gland—breast cancer	0.00127	0.0225	CbGeAlD
Nedocromil—CYSLTR1—endocrine gland—breast cancer	0.00127	0.0225	CbGeAlD
Nedocromil—HSP90AA1—bone marrow—breast cancer	0.00123	0.0218	CbGeAlD
Nedocromil—HSP90AA1—female gonad—breast cancer	0.00119	0.021	CbGeAlD
Nedocromil—HSP90AA1—endocrine gland—breast cancer	0.0011	0.0195	CbGeAlD
Nedocromil—CYSLTR1—lymph node—breast cancer	0.000879	0.0156	CbGeAlD
Nedocromil—HSP90AA1—lymph node—breast cancer	0.000763	0.0135	CbGeAlD
Nedocromil—Dyspepsia—Mitoxantrone—breast cancer	0.00011	0.000871	CcSEcCtD
Nedocromil—Dyspepsia—Irinotecan—breast cancer	0.00011	0.000871	CcSEcCtD
Nedocromil—Rash—Melphalan—breast cancer	0.000109	0.000866	CcSEcCtD
Nedocromil—Dermatitis—Melphalan—breast cancer	0.000109	0.000865	CcSEcCtD
Nedocromil—Cough—Paclitaxel—breast cancer	0.000109	0.000863	CcSEcCtD
Nedocromil—Asthenia—Vinorelbine—breast cancer	0.000109	0.000861	CcSEcCtD
Nedocromil—Dyspnoea—Gemcitabine—breast cancer	0.000108	0.000859	CcSEcCtD
Nedocromil—Eosinophilia—Methotrexate—breast cancer	0.000108	0.000858	CcSEcCtD
Nedocromil—Nausea—Vinblastine—breast cancer	0.000108	0.000858	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Irinotecan—breast cancer	0.000108	0.000854	CcSEcCtD
Nedocromil—Fatigue—Mitoxantrone—breast cancer	0.000108	0.000853	CcSEcCtD
Nedocromil—Fatigue—Irinotecan—breast cancer	0.000108	0.000853	CcSEcCtD
Nedocromil—Vomiting—Goserelin—breast cancer	0.000108	0.000852	CcSEcCtD
Nedocromil—Pain—Irinotecan—breast cancer	0.000107	0.000846	CcSEcCtD
Nedocromil—Pain—Mitoxantrone—breast cancer	0.000107	0.000846	CcSEcCtD
Nedocromil—Dyspnoea—Fluorouracil—breast cancer	0.000107	0.000845	CcSEcCtD
Nedocromil—Rash—Goserelin—breast cancer	0.000107	0.000845	CcSEcCtD
Nedocromil—Hypersensitivity—Thiotepa—breast cancer	0.000107	0.000844	CcSEcCtD
Nedocromil—Dermatitis—Goserelin—breast cancer	0.000107	0.000844	CcSEcCtD
Nedocromil—Chest pain—Paclitaxel—breast cancer	0.000106	0.000842	CcSEcCtD
Nedocromil—Headache—Goserelin—breast cancer	0.000106	0.000839	CcSEcCtD
Nedocromil—Dyspepsia—Fluorouracil—breast cancer	0.000105	0.000834	CcSEcCtD
Nedocromil—Nausea—Tamoxifen—breast cancer	0.000105	0.000833	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Gemcitabine—breast cancer	0.000105	0.000832	CcSEcCtD
Nedocromil—Fatigue—Gemcitabine—breast cancer	0.000105	0.000831	CcSEcCtD
Nedocromil—Pain—Gemcitabine—breast cancer	0.000104	0.000824	CcSEcCtD
Nedocromil—Dry mouth—Paclitaxel—breast cancer	0.000104	0.000823	CcSEcCtD
Nedocromil—Asthenia—Thiotepa—breast cancer	0.000104	0.000822	CcSEcCtD
Nedocromil—Diarrhoea—Vinorelbine—breast cancer	0.000104	0.000821	CcSEcCtD
Nedocromil—Dysgeusia—Docetaxel—breast cancer	0.000104	0.000821	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Fluorouracil—breast cancer	0.000103	0.000818	CcSEcCtD
Nedocromil—Nausea—Melphalan—breast cancer	0.000103	0.000816	CcSEcCtD
Nedocromil—Influenza—Epirubicin—breast cancer	0.000102	0.000811	CcSEcCtD
Nedocromil—Pain—Fluorouracil—breast cancer	0.000102	0.00081	CcSEcCtD
Nedocromil—Gastrointestinal pain—Mitoxantrone—breast cancer	0.000102	0.000809	CcSEcCtD
Nedocromil—Gastrointestinal pain—Irinotecan—breast cancer	0.000102	0.000809	CcSEcCtD
Nedocromil—Anaphylactic shock—Paclitaxel—breast cancer	0.000102	0.000807	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Methotrexate—breast cancer	0.000102	0.000806	CcSEcCtD
Nedocromil—Eosinophilia—Epirubicin—breast cancer	0.000101	0.000803	CcSEcCtD
Nedocromil—Nausea—Goserelin—breast cancer	0.0001	0.000796	CcSEcCtD
Nedocromil—Dysgeusia—Capecitabine—breast cancer	0.0001	0.000795	CcSEcCtD
Nedocromil—Dizziness—Vinorelbine—breast cancer	0.0001	0.000793	CcSEcCtD
Nedocromil—Urticaria—Mitoxantrone—breast cancer	9.92e-05	0.000786	CcSEcCtD
Nedocromil—Diarrhoea—Thiotepa—breast cancer	9.9e-05	0.000784	CcSEcCtD
Nedocromil—Body temperature increased—Irinotecan—breast cancer	9.88e-05	0.000782	CcSEcCtD
Nedocromil—Abdominal pain—Mitoxantrone—breast cancer	9.88e-05	0.000782	CcSEcCtD
Nedocromil—Abdominal pain—Irinotecan—breast cancer	9.88e-05	0.000782	CcSEcCtD
Nedocromil—Body temperature increased—Mitoxantrone—breast cancer	9.88e-05	0.000782	CcSEcCtD
Nedocromil—Bronchitis—Epirubicin—breast cancer	9.85e-05	0.00078	CcSEcCtD
Nedocromil—Pneumonia—Methotrexate—breast cancer	9.82e-05	0.000777	CcSEcCtD
Nedocromil—Vomiting—Vinorelbine—breast cancer	9.63e-05	0.000763	CcSEcCtD
Nedocromil—Body temperature increased—Gemcitabine—breast cancer	9.62e-05	0.000762	CcSEcCtD
Nedocromil—Tremor—Capecitabine—breast cancer	9.6e-05	0.00076	CcSEcCtD
Nedocromil—Dizziness—Thiotepa—breast cancer	9.57e-05	0.000758	CcSEcCtD
Nedocromil—Rash—Vinorelbine—breast cancer	9.55e-05	0.000756	CcSEcCtD
Nedocromil—Dermatitis—Vinorelbine—breast cancer	9.54e-05	0.000756	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Epirubicin—breast cancer	9.52e-05	0.000754	CcSEcCtD
Nedocromil—Urticaria—Fluorouracil—breast cancer	9.51e-05	0.000753	CcSEcCtD
Nedocromil—Headache—Vinorelbine—breast cancer	9.49e-05	0.000752	CcSEcCtD
Nedocromil—Conjunctivitis—Methotrexate—breast cancer	9.49e-05	0.000751	CcSEcCtD
Nedocromil—Influenza—Doxorubicin—breast cancer	9.48e-05	0.000751	CcSEcCtD
Nedocromil—Leukopenia—Docetaxel—breast cancer	9.47e-05	0.00075	CcSEcCtD
Nedocromil—Body temperature increased—Fluorouracil—breast cancer	9.46e-05	0.000749	CcSEcCtD
Nedocromil—Eosinophilia—Doxorubicin—breast cancer	9.38e-05	0.000743	CcSEcCtD
Nedocromil—Cough—Docetaxel—breast cancer	9.23e-05	0.000731	CcSEcCtD
Nedocromil—Hypersensitivity—Mitoxantrone—breast cancer	9.2e-05	0.000729	CcSEcCtD
Nedocromil—Hypersensitivity—Irinotecan—breast cancer	9.2e-05	0.000729	CcSEcCtD
Nedocromil—Vomiting—Thiotepa—breast cancer	9.2e-05	0.000729	CcSEcCtD
Nedocromil—Pneumonia—Epirubicin—breast cancer	9.19e-05	0.000728	CcSEcCtD
Nedocromil—Leukopenia—Capecitabine—breast cancer	9.17e-05	0.000726	CcSEcCtD
Nedocromil—Rash—Thiotepa—breast cancer	9.12e-05	0.000722	CcSEcCtD
Nedocromil—Bronchitis—Doxorubicin—breast cancer	9.11e-05	0.000722	CcSEcCtD
Nedocromil—Dermatitis—Thiotepa—breast cancer	9.11e-05	0.000722	CcSEcCtD
Nedocromil—Dyspnoea—Paclitaxel—breast cancer	9.08e-05	0.000719	CcSEcCtD
Nedocromil—Headache—Thiotepa—breast cancer	9.06e-05	0.000718	CcSEcCtD
Nedocromil—Chest pain—Docetaxel—breast cancer	9.01e-05	0.000714	CcSEcCtD
Nedocromil—Nausea—Vinorelbine—breast cancer	9e-05	0.000713	CcSEcCtD
Nedocromil—Dyspepsia—Paclitaxel—breast cancer	8.97e-05	0.00071	CcSEcCtD
Nedocromil—Asthenia—Mitoxantrone—breast cancer	8.96e-05	0.00071	CcSEcCtD
Nedocromil—Asthenia—Irinotecan—breast cancer	8.96e-05	0.00071	CcSEcCtD
Nedocromil—Cough—Capecitabine—breast cancer	8.94e-05	0.000708	CcSEcCtD
Nedocromil—Conjunctivitis—Epirubicin—breast cancer	8.88e-05	0.000703	CcSEcCtD
Nedocromil—Hypersensitivity—Fluorouracil—breast cancer	8.82e-05	0.000698	CcSEcCtD
Nedocromil—Dry mouth—Docetaxel—breast cancer	8.81e-05	0.000698	CcSEcCtD
Nedocromil—Upper respiratory tract infection—Doxorubicin—breast cancer	8.81e-05	0.000698	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Paclitaxel—breast cancer	8.8e-05	0.000697	CcSEcCtD
Nedocromil—Fatigue—Paclitaxel—breast cancer	8.78e-05	0.000696	CcSEcCtD
Nedocromil—Asthenia—Gemcitabine—breast cancer	8.73e-05	0.000692	CcSEcCtD
Nedocromil—Chest pain—Capecitabine—breast cancer	8.72e-05	0.000691	CcSEcCtD
Nedocromil—Pain—Paclitaxel—breast cancer	8.71e-05	0.00069	CcSEcCtD
Nedocromil—Pharyngitis—Methotrexate—breast cancer	8.7e-05	0.000689	CcSEcCtD
Nedocromil—Anaphylactic shock—Docetaxel—breast cancer	8.64e-05	0.000684	CcSEcCtD
Nedocromil—Nausea—Thiotepa—breast cancer	8.59e-05	0.000681	CcSEcCtD
Nedocromil—Sinusitis—Epirubicin—breast cancer	8.57e-05	0.000679	CcSEcCtD
Nedocromil—Diarrhoea—Mitoxantrone—breast cancer	8.55e-05	0.000677	CcSEcCtD
Nedocromil—Diarrhoea—Irinotecan—breast cancer	8.55e-05	0.000677	CcSEcCtD
Nedocromil—Dry mouth—Capecitabine—breast cancer	8.53e-05	0.000676	CcSEcCtD
Nedocromil—Pneumonia—Doxorubicin—breast cancer	8.5e-05	0.000673	CcSEcCtD
Nedocromil—Visual impairment—Methotrexate—breast cancer	8.44e-05	0.000669	CcSEcCtD
Nedocromil—Gastrointestinal pain—Paclitaxel—breast cancer	8.33e-05	0.00066	CcSEcCtD
Nedocromil—Diarrhoea—Gemcitabine—breast cancer	8.33e-05	0.000659	CcSEcCtD
Nedocromil—Dizziness—Irinotecan—breast cancer	8.26e-05	0.000654	CcSEcCtD
Nedocromil—Rhinitis—Epirubicin—breast cancer	8.22e-05	0.000651	CcSEcCtD
Nedocromil—Conjunctivitis—Doxorubicin—breast cancer	8.21e-05	0.000651	CcSEcCtD
Nedocromil—Diarrhoea—Fluorouracil—breast cancer	8.19e-05	0.000648	CcSEcCtD
Nedocromil—Pharyngitis—Epirubicin—breast cancer	8.14e-05	0.000645	CcSEcCtD
Nedocromil—Urticaria—Paclitaxel—breast cancer	8.09e-05	0.000641	CcSEcCtD
Nedocromil—Abdominal pain—Paclitaxel—breast cancer	8.05e-05	0.000638	CcSEcCtD
Nedocromil—Body temperature increased—Paclitaxel—breast cancer	8.05e-05	0.000638	CcSEcCtD
Nedocromil—Vomiting—Mitoxantrone—breast cancer	7.94e-05	0.000629	CcSEcCtD
Nedocromil—Vomiting—Irinotecan—breast cancer	7.94e-05	0.000629	CcSEcCtD
Nedocromil—Sinusitis—Doxorubicin—breast cancer	7.93e-05	0.000628	CcSEcCtD
Nedocromil—Dizziness—Fluorouracil—breast cancer	7.91e-05	0.000627	CcSEcCtD
Nedocromil—Visual impairment—Epirubicin—breast cancer	7.9e-05	0.000626	CcSEcCtD
Nedocromil—Rash—Mitoxantrone—breast cancer	7.88e-05	0.000624	CcSEcCtD
Nedocromil—Rash—Irinotecan—breast cancer	7.88e-05	0.000624	CcSEcCtD
Nedocromil—Dermatitis—Irinotecan—breast cancer	7.87e-05	0.000623	CcSEcCtD
Nedocromil—Dermatitis—Mitoxantrone—breast cancer	7.87e-05	0.000623	CcSEcCtD
Nedocromil—Headache—Mitoxantrone—breast cancer	7.83e-05	0.00062	CcSEcCtD
Nedocromil—Headache—Irinotecan—breast cancer	7.83e-05	0.00062	CcSEcCtD
Nedocromil—Vomiting—Gemcitabine—breast cancer	7.74e-05	0.000613	CcSEcCtD
Nedocromil—Dyspnoea—Docetaxel—breast cancer	7.7e-05	0.00061	CcSEcCtD
Nedocromil—Rash—Gemcitabine—breast cancer	7.67e-05	0.000608	CcSEcCtD
Nedocromil—Dermatitis—Gemcitabine—breast cancer	7.67e-05	0.000607	CcSEcCtD
Nedocromil—Headache—Gemcitabine—breast cancer	7.62e-05	0.000604	CcSEcCtD
Nedocromil—Vomiting—Fluorouracil—breast cancer	7.61e-05	0.000603	CcSEcCtD
Nedocromil—Rhinitis—Doxorubicin—breast cancer	7.61e-05	0.000602	CcSEcCtD
Nedocromil—Dyspepsia—Docetaxel—breast cancer	7.6e-05	0.000602	CcSEcCtD
Nedocromil—Rash—Fluorouracil—breast cancer	7.54e-05	0.000598	CcSEcCtD
Nedocromil—Dermatitis—Fluorouracil—breast cancer	7.54e-05	0.000597	CcSEcCtD
Nedocromil—Pharyngitis—Doxorubicin—breast cancer	7.53e-05	0.000596	CcSEcCtD
Nedocromil—Hypersensitivity—Paclitaxel—breast cancer	7.51e-05	0.000595	CcSEcCtD
Nedocromil—Headache—Fluorouracil—breast cancer	7.5e-05	0.000594	CcSEcCtD
Nedocromil—Dysgeusia—Methotrexate—breast cancer	7.47e-05	0.000592	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Docetaxel—breast cancer	7.46e-05	0.000591	CcSEcCtD
Nedocromil—Dyspnoea—Capecitabine—breast cancer	7.45e-05	0.00059	CcSEcCtD
Nedocromil—Fatigue—Docetaxel—breast cancer	7.45e-05	0.00059	CcSEcCtD
Nedocromil—Nausea—Irinotecan—breast cancer	7.42e-05	0.000588	CcSEcCtD
Nedocromil—Nausea—Mitoxantrone—breast cancer	7.42e-05	0.000588	CcSEcCtD
Nedocromil—Pain—Docetaxel—breast cancer	7.38e-05	0.000585	CcSEcCtD
Nedocromil—Dyspepsia—Capecitabine—breast cancer	7.36e-05	0.000583	CcSEcCtD
Nedocromil—Visual impairment—Doxorubicin—breast cancer	7.31e-05	0.000579	CcSEcCtD
Nedocromil—Asthenia—Paclitaxel—breast cancer	7.31e-05	0.000579	CcSEcCtD
Nedocromil—Nausea—Gemcitabine—breast cancer	7.23e-05	0.000573	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Capecitabine—breast cancer	7.22e-05	0.000572	CcSEcCtD
Nedocromil—Fatigue—Capecitabine—breast cancer	7.21e-05	0.000571	CcSEcCtD
Nedocromil—Pain—Capecitabine—breast cancer	7.15e-05	0.000566	CcSEcCtD
Nedocromil—Nausea—Fluorouracil—breast cancer	7.11e-05	0.000563	CcSEcCtD
Nedocromil—Gastrointestinal pain—Docetaxel—breast cancer	7.06e-05	0.000559	CcSEcCtD
Nedocromil—Dysgeusia—Epirubicin—breast cancer	6.99e-05	0.000554	CcSEcCtD
Nedocromil—Diarrhoea—Paclitaxel—breast cancer	6.97e-05	0.000552	CcSEcCtD
Nedocromil—Gastrointestinal pain—Capecitabine—breast cancer	6.84e-05	0.000542	CcSEcCtD
Nedocromil—Body temperature increased—Docetaxel—breast cancer	6.83e-05	0.000541	CcSEcCtD
Nedocromil—Abdominal pain—Docetaxel—breast cancer	6.83e-05	0.000541	CcSEcCtD
Nedocromil—Leukopenia—Methotrexate—breast cancer	6.83e-05	0.000541	CcSEcCtD
Nedocromil—Dizziness—Paclitaxel—breast cancer	6.74e-05	0.000534	CcSEcCtD
Nedocromil—Cough—Methotrexate—breast cancer	6.65e-05	0.000527	CcSEcCtD
Nedocromil—Urticaria—Capecitabine—breast cancer	6.64e-05	0.000526	CcSEcCtD
Nedocromil—Abdominal pain—Capecitabine—breast cancer	6.61e-05	0.000524	CcSEcCtD
Nedocromil—Body temperature increased—Capecitabine—breast cancer	6.61e-05	0.000524	CcSEcCtD
Nedocromil—Chest pain—Methotrexate—breast cancer	6.49e-05	0.000514	CcSEcCtD
Nedocromil—Vomiting—Paclitaxel—breast cancer	6.48e-05	0.000513	CcSEcCtD
Nedocromil—Dysgeusia—Doxorubicin—breast cancer	6.47e-05	0.000512	CcSEcCtD
Nedocromil—Rash—Paclitaxel—breast cancer	6.42e-05	0.000509	CcSEcCtD
Nedocromil—Dermatitis—Paclitaxel—breast cancer	6.42e-05	0.000508	CcSEcCtD
Nedocromil—Leukopenia—Epirubicin—breast cancer	6.39e-05	0.000506	CcSEcCtD
Nedocromil—Headache—Paclitaxel—breast cancer	6.38e-05	0.000506	CcSEcCtD
Nedocromil—Hypersensitivity—Docetaxel—breast cancer	6.36e-05	0.000504	CcSEcCtD
Nedocromil—Cough—Epirubicin—breast cancer	6.23e-05	0.000493	CcSEcCtD
Nedocromil—Anaphylactic shock—Methotrexate—breast cancer	6.22e-05	0.000493	CcSEcCtD
Nedocromil—Asthenia—Docetaxel—breast cancer	6.2e-05	0.000491	CcSEcCtD
Nedocromil—Hypersensitivity—Capecitabine—breast cancer	6.16e-05	0.000488	CcSEcCtD
Nedocromil—Chest pain—Epirubicin—breast cancer	6.08e-05	0.000481	CcSEcCtD
Nedocromil—Nausea—Paclitaxel—breast cancer	6.05e-05	0.000479	CcSEcCtD
Nedocromil—Asthenia—Capecitabine—breast cancer	6e-05	0.000475	CcSEcCtD
Nedocromil—Dry mouth—Epirubicin—breast cancer	5.94e-05	0.000471	CcSEcCtD
Nedocromil—Leukopenia—Doxorubicin—breast cancer	5.91e-05	0.000468	CcSEcCtD
Nedocromil—Diarrhoea—Docetaxel—breast cancer	5.91e-05	0.000468	CcSEcCtD
Nedocromil—Anaphylactic shock—Epirubicin—breast cancer	5.82e-05	0.000461	CcSEcCtD
Nedocromil—Cough—Doxorubicin—breast cancer	5.76e-05	0.000456	CcSEcCtD
Nedocromil—Diarrhoea—Capecitabine—breast cancer	5.72e-05	0.000453	CcSEcCtD
Nedocromil—Dizziness—Docetaxel—breast cancer	5.71e-05	0.000452	CcSEcCtD
Nedocromil—Chest pain—Doxorubicin—breast cancer	5.62e-05	0.000445	CcSEcCtD
Nedocromil—Dyspnoea—Methotrexate—breast cancer	5.55e-05	0.00044	CcSEcCtD
Nedocromil—Dizziness—Capecitabine—breast cancer	5.53e-05	0.000438	CcSEcCtD
Nedocromil—Dry mouth—Doxorubicin—breast cancer	5.5e-05	0.000436	CcSEcCtD
Nedocromil—Vomiting—Docetaxel—breast cancer	5.49e-05	0.000435	CcSEcCtD
Nedocromil—Dyspepsia—Methotrexate—breast cancer	5.48e-05	0.000434	CcSEcCtD
Nedocromil—Rash—Docetaxel—breast cancer	5.45e-05	0.000431	CcSEcCtD
Nedocromil—Dermatitis—Docetaxel—breast cancer	5.44e-05	0.000431	CcSEcCtD
Nedocromil—Headache—Docetaxel—breast cancer	5.41e-05	0.000429	CcSEcCtD
Nedocromil—Anaphylactic shock—Doxorubicin—breast cancer	5.39e-05	0.000427	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Methotrexate—breast cancer	5.37e-05	0.000426	CcSEcCtD
Nedocromil—Fatigue—Methotrexate—breast cancer	5.37e-05	0.000425	CcSEcCtD
Nedocromil—Pain—Methotrexate—breast cancer	5.32e-05	0.000422	CcSEcCtD
Nedocromil—Vomiting—Capecitabine—breast cancer	5.32e-05	0.000421	CcSEcCtD
Nedocromil—Rash—Capecitabine—breast cancer	5.27e-05	0.000418	CcSEcCtD
Nedocromil—Dermatitis—Capecitabine—breast cancer	5.27e-05	0.000417	CcSEcCtD
Nedocromil—Headache—Capecitabine—breast cancer	5.24e-05	0.000415	CcSEcCtD
Nedocromil—Dyspnoea—Epirubicin—breast cancer	5.19e-05	0.000411	CcSEcCtD
Nedocromil—Nausea—Docetaxel—breast cancer	5.13e-05	0.000406	CcSEcCtD
Nedocromil—Dyspepsia—Epirubicin—breast cancer	5.13e-05	0.000406	CcSEcCtD
Nedocromil—Gastrointestinal pain—Methotrexate—breast cancer	5.09e-05	0.000403	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Epirubicin—breast cancer	5.03e-05	0.000398	CcSEcCtD
Nedocromil—Fatigue—Epirubicin—breast cancer	5.02e-05	0.000398	CcSEcCtD
Nedocromil—Pain—Epirubicin—breast cancer	4.98e-05	0.000395	CcSEcCtD
Nedocromil—Nausea—Capecitabine—breast cancer	4.97e-05	0.000393	CcSEcCtD
Nedocromil—Urticaria—Methotrexate—breast cancer	4.94e-05	0.000392	CcSEcCtD
Nedocromil—Abdominal pain—Methotrexate—breast cancer	4.92e-05	0.00039	CcSEcCtD
Nedocromil—Body temperature increased—Methotrexate—breast cancer	4.92e-05	0.00039	CcSEcCtD
Nedocromil—Dyspnoea—Doxorubicin—breast cancer	4.8e-05	0.000381	CcSEcCtD
Nedocromil—Gastrointestinal pain—Epirubicin—breast cancer	4.76e-05	0.000377	CcSEcCtD
Nedocromil—Dyspepsia—Doxorubicin—breast cancer	4.74e-05	0.000376	CcSEcCtD
Nedocromil—Gastrointestinal disorder—Doxorubicin—breast cancer	4.65e-05	0.000369	CcSEcCtD
Nedocromil—Fatigue—Doxorubicin—breast cancer	4.65e-05	0.000368	CcSEcCtD
Nedocromil—Urticaria—Epirubicin—breast cancer	4.63e-05	0.000367	CcSEcCtD
Nedocromil—Pain—Doxorubicin—breast cancer	4.61e-05	0.000365	CcSEcCtD
Nedocromil—Abdominal pain—Epirubicin—breast cancer	4.6e-05	0.000365	CcSEcCtD
Nedocromil—Body temperature increased—Epirubicin—breast cancer	4.6e-05	0.000365	CcSEcCtD
Nedocromil—Hypersensitivity—Methotrexate—breast cancer	4.59e-05	0.000363	CcSEcCtD
Nedocromil—Asthenia—Methotrexate—breast cancer	4.47e-05	0.000354	CcSEcCtD
Nedocromil—Gastrointestinal pain—Doxorubicin—breast cancer	4.41e-05	0.000349	CcSEcCtD
Nedocromil—Hypersensitivity—Epirubicin—breast cancer	4.29e-05	0.00034	CcSEcCtD
Nedocromil—Urticaria—Doxorubicin—breast cancer	4.28e-05	0.000339	CcSEcCtD
Nedocromil—Body temperature increased—Doxorubicin—breast cancer	4.26e-05	0.000337	CcSEcCtD
Nedocromil—Abdominal pain—Doxorubicin—breast cancer	4.26e-05	0.000337	CcSEcCtD
Nedocromil—Diarrhoea—Methotrexate—breast cancer	4.26e-05	0.000337	CcSEcCtD
Nedocromil—Asthenia—Epirubicin—breast cancer	4.18e-05	0.000331	CcSEcCtD
Nedocromil—Dizziness—Methotrexate—breast cancer	4.12e-05	0.000326	CcSEcCtD
Nedocromil—Diarrhoea—Epirubicin—breast cancer	3.99e-05	0.000316	CcSEcCtD
Nedocromil—Hypersensitivity—Doxorubicin—breast cancer	3.97e-05	0.000315	CcSEcCtD
Nedocromil—Vomiting—Methotrexate—breast cancer	3.96e-05	0.000313	CcSEcCtD
Nedocromil—Rash—Methotrexate—breast cancer	3.92e-05	0.000311	CcSEcCtD
Nedocromil—Dermatitis—Methotrexate—breast cancer	3.92e-05	0.000311	CcSEcCtD
Nedocromil—Headache—Methotrexate—breast cancer	3.9e-05	0.000309	CcSEcCtD
Nedocromil—Asthenia—Doxorubicin—breast cancer	3.87e-05	0.000306	CcSEcCtD
Nedocromil—Dizziness—Epirubicin—breast cancer	3.85e-05	0.000305	CcSEcCtD
Nedocromil—Vomiting—Epirubicin—breast cancer	3.7e-05	0.000293	CcSEcCtD
Nedocromil—Nausea—Methotrexate—breast cancer	3.7e-05	0.000293	CcSEcCtD
Nedocromil—Diarrhoea—Doxorubicin—breast cancer	3.69e-05	0.000292	CcSEcCtD
Nedocromil—Rash—Epirubicin—breast cancer	3.67e-05	0.000291	CcSEcCtD
Nedocromil—Dermatitis—Epirubicin—breast cancer	3.67e-05	0.000291	CcSEcCtD
Nedocromil—Headache—Epirubicin—breast cancer	3.65e-05	0.000289	CcSEcCtD
Nedocromil—Dizziness—Doxorubicin—breast cancer	3.56e-05	0.000282	CcSEcCtD
Nedocromil—Nausea—Epirubicin—breast cancer	3.46e-05	0.000274	CcSEcCtD
Nedocromil—Vomiting—Doxorubicin—breast cancer	3.43e-05	0.000271	CcSEcCtD
Nedocromil—Rash—Doxorubicin—breast cancer	3.4e-05	0.000269	CcSEcCtD
Nedocromil—Dermatitis—Doxorubicin—breast cancer	3.4e-05	0.000269	CcSEcCtD
Nedocromil—Headache—Doxorubicin—breast cancer	3.38e-05	0.000267	CcSEcCtD
Nedocromil—Nausea—Doxorubicin—breast cancer	3.2e-05	0.000254	CcSEcCtD
Nedocromil—HSP90AA1—Disease—NOS2—breast cancer	7.95e-06	4.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ESR1—breast cancer	7.94e-06	4.9e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—HRAS—breast cancer	7.93e-06	4.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFBR2—breast cancer	7.9e-06	4.87e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOTCH1—breast cancer	7.87e-06	4.85e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—MYC—breast cancer	7.87e-06	4.85e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—FN1—breast cancer	7.85e-06	4.84e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TGFB1—breast cancer	7.85e-06	4.84e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MAPK3—breast cancer	7.81e-06	4.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1B—breast cancer	7.79e-06	4.8e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ITPR1—breast cancer	7.77e-06	4.79e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CASP8—breast cancer	7.76e-06	4.78e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NFKBIA—breast cancer	7.75e-06	4.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB4—breast cancer	7.72e-06	4.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP3—breast cancer	7.72e-06	4.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT5A—breast cancer	7.72e-06	4.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—GPCR downstream signaling—AKT1—breast cancer	7.71e-06	4.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—EGFR—breast cancer	7.7e-06	4.75e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KIT—breast cancer	7.7e-06	4.74e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—APC—breast cancer	7.7e-06	4.74e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—EGFR—breast cancer	7.69e-06	4.74e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOTCH1—breast cancer	7.68e-06	4.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDH1—breast cancer	7.67e-06	4.73e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—MTHFR—breast cancer	7.67e-06	4.73e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CASP3—breast cancer	7.64e-06	4.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT2—breast cancer	7.63e-06	4.7e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL2—breast cancer	7.62e-06	4.7e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGF—breast cancer	7.61e-06	4.69e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—MYC—breast cancer	7.6e-06	4.68e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—IL6—breast cancer	7.59e-06	4.67e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TGFB1—breast cancer	7.58e-06	4.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—APC—breast cancer	7.51e-06	4.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CG—breast cancer	7.51e-06	4.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KIT—breast cancer	7.51e-06	4.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SMAD4—breast cancer	7.48e-06	4.61e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CCND1—breast cancer	7.43e-06	4.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1R—breast cancer	7.43e-06	4.58e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—EGFR—breast cancer	7.43e-06	4.58e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGF—breast cancer	7.42e-06	4.57e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—JUN—breast cancer	7.42e-06	4.57e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CTNNB1—breast cancer	7.36e-06	4.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CD—breast cancer	7.33e-06	4.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HES1—breast cancer	7.3e-06	4.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—KRAS—breast cancer	7.28e-06	4.48e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—KRAS—breast cancer	7.27e-06	4.48e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NCOR1—breast cancer	7.26e-06	4.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PLA2G4A—breast cancer	7.26e-06	4.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—BRAF—breast cancer	7.24e-06	4.46e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MMP9—breast cancer	7.22e-06	4.45e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—MAPK3—breast cancer	7.19e-06	4.43e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—CDKN1A—breast cancer	7.19e-06	4.43e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CSF2—breast cancer	7.18e-06	4.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGF1—breast cancer	7.18e-06	4.42e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PTEN—breast cancer	7.17e-06	4.42e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NRG1—breast cancer	7.13e-06	4.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—CAV1—breast cancer	7.08e-06	4.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—H2AFX—breast cancer	7.07e-06	4.36e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—BRAF—breast cancer	7.06e-06	4.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT2—breast cancer	7.04e-06	4.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—E2F1—breast cancer	7.02e-06	4.33e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—KRAS—breast cancer	7.02e-06	4.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK8—breast cancer	7.02e-06	4.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—HRAS—breast cancer	7e-06	4.32e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling by GPCR—AKT1—breast cancer	7e-06	4.31e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IGF1—breast cancer	6.88e-06	4.24e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT2—breast cancer	6.87e-06	4.23e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—EGFR—breast cancer	6.84e-06	4.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Cell Cycle—TP53—breast cancer	6.78e-06	4.18e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CD—breast cancer	6.77e-06	4.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SPP1—breast cancer	6.75e-06	4.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—IL6—breast cancer	6.7e-06	4.13e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SERPINE1—breast cancer	6.69e-06	4.12e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—PIK3CA—breast cancer	6.69e-06	4.12e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—PIK3CA—breast cancer	6.68e-06	4.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB3—breast cancer	6.68e-06	4.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR2—breast cancer	6.66e-06	4.11e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—BCL2—breast cancer	6.66e-06	4.11e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—SRC—breast cancer	6.65e-06	4.1e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IFNG—breast cancer	6.6e-06	4.07e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CD—breast cancer	6.6e-06	4.07e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MDM2—breast cancer	6.57e-06	4.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—RAF1—breast cancer	6.54e-06	4.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—PIK3CA—breast cancer	6.54e-06	4.03e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SERPINE1—breast cancer	6.53e-06	4.02e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—RELA—breast cancer	6.51e-06	4.01e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—VEGFA—breast cancer	6.48e-06	3.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—ERBB2—breast cancer	6.47e-06	3.99e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—KRAS—breast cancer	6.46e-06	3.98e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—TP53—breast cancer	6.46e-06	3.98e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—PIK3CA—breast cancer	6.45e-06	3.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CG—breast cancer	6.45e-06	3.97e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—STAT3—breast cancer	6.42e-06	3.95e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TERT—breast cancer	6.4e-06	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—NOS3—breast cancer	6.39e-06	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MTOR—breast cancer	6.39e-06	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CB—breast cancer	6.39e-06	3.94e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CD4—breast cancer	6.38e-06	3.93e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—TP53—breast cancer	6.24e-06	3.84e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—NOS3—breast cancer	6.23e-06	3.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FGFR1—breast cancer	6.21e-06	3.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—HRAS—breast cancer	6.19e-06	3.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Developmental Biology—AKT1—breast cancer	6.18e-06	3.81e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—HRAS—breast cancer	6.18e-06	3.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MAPK3—breast cancer	6.13e-06	3.78e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HIF1A—breast cancer	6.12e-06	3.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MDM2—breast cancer	6.06e-06	3.74e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—RAF1—breast cancer	6.04e-06	3.72e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1B—breast cancer	6e-06	3.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—ERBB2—breast cancer	5.98e-06	3.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—LEP—breast cancer	5.97e-06	3.68e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—HRAS—breast cancer	5.97e-06	3.68e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—MYC—breast cancer	5.96e-06	3.67e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TGFB1—breast cancer	5.95e-06	3.66e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—PIK3CA—breast cancer	5.94e-06	3.66e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—IL6—breast cancer	5.92e-06	3.65e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CAV1—breast cancer	5.92e-06	3.65e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MDM2—breast cancer	5.91e-06	3.64e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—IL6—breast cancer	5.91e-06	3.64e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CB—breast cancer	5.9e-06	3.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MTOR—breast cancer	5.9e-06	3.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RAF1—breast cancer	5.89e-06	3.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL1B—breast cancer	5.89e-06	3.63e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CD4—breast cancer	5.89e-06	3.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—RELA—breast cancer	5.87e-06	3.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL2—breast cancer	5.87e-06	3.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KDR—breast cancer	5.85e-06	3.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTGS2—breast cancer	5.84e-06	3.6e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—ERBB2—breast cancer	5.83e-06	3.59e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—EGFR—breast cancer	5.83e-06	3.59e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MTOR—breast cancer	5.75e-06	3.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CB—breast cancer	5.75e-06	3.55e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—IL6—breast cancer	5.71e-06	3.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—JUN—breast cancer	5.71e-06	3.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ESR1—breast cancer	5.7e-06	3.51e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CD—breast cancer	5.67e-06	3.49e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CTNNB1—breast cancer	5.66e-06	3.49e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—FN1—breast cancer	5.63e-06	3.47e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—ALB—breast cancer	5.59e-06	3.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NFKBIA—breast cancer	5.57e-06	3.43e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1B—breast cancer	5.54e-06	3.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—CDKN1A—breast cancer	5.53e-06	3.41e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CXCL8—breast cancer	5.53e-06	3.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PTEN—breast cancer	5.52e-06	3.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOTCH1—breast cancer	5.51e-06	3.4e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—KRAS—breast cancer	5.51e-06	3.39e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—HRAS—breast cancer	5.49e-06	3.39e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Innate Immune System—AKT1—breast cancer	5.46e-06	3.37e-05	CbGpPWpGaD
Nedocromil—FPR1—Signaling Pathways—AKT1—breast cancer	5.46e-06	3.36e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK8—breast cancer	5.4e-06	3.33e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1B—breast cancer	5.4e-06	3.33e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KIT—breast cancer	5.39e-06	3.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CG—breast cancer	5.39e-06	3.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—APC—breast cancer	5.39e-06	3.32e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—NOS3—breast cancer	5.35e-06	3.3e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—GPCR downstream signaling—AKT1—breast cancer	5.34e-06	3.29e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGF—breast cancer	5.33e-06	3.28e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CASP3—breast cancer	5.29e-06	3.26e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL2—breast cancer	5.28e-06	3.26e-05	CbGpPWpGaD
Nedocromil—PTGDR—Signaling Pathways—AKT1—breast cancer	5.27e-06	3.25e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—IL6—breast cancer	5.26e-06	3.24e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CTNNB1—breast cancer	5.23e-06	3.22e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CCND1—breast cancer	5.15e-06	3.17e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—JUN—breast cancer	5.14e-06	3.17e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—SRC—breast cancer	5.12e-06	3.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—CDKN1A—breast cancer	5.11e-06	3.15e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CTNNB1—breast cancer	5.1e-06	3.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PTEN—breast cancer	5.1e-06	3.14e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—BRAF—breast cancer	5.07e-06	3.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—PIK3CA—breast cancer	5.06e-06	3.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MMP9—breast cancer	5e-06	3.08e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—CDKN1A—breast cancer	4.98e-06	3.07e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PTEN—breast cancer	4.97e-06	3.06e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CB—breast cancer	4.94e-06	3.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—STAT3—breast cancer	4.94e-06	3.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IGF1—breast cancer	4.94e-06	3.04e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT2—breast cancer	4.93e-06	3.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—TP53—breast cancer	4.9e-06	3.02e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTGS2—breast cancer	4.89e-06	3.02e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK8—breast cancer	4.86e-06	3e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling by GPCR—AKT1—breast cancer	4.85e-06	2.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CD—breast cancer	4.74e-06	2.92e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—SRC—breast cancer	4.73e-06	2.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—MAPK3—breast cancer	4.72e-06	2.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SERPINE1—breast cancer	4.69e-06	2.89e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—HRAS—breast cancer	4.68e-06	2.88e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—SRC—breast cancer	4.61e-06	2.84e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—STAT3—breast cancer	4.56e-06	2.81e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—VEGFA—breast cancer	4.49e-06	2.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—EGFR—breast cancer	4.49e-06	2.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—IL6—breast cancer	4.48e-06	2.76e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—NOS3—breast cancer	4.47e-06	2.76e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—STAT3—breast cancer	4.45e-06	2.74e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MAPK3—breast cancer	4.35e-06	2.68e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PTEN—breast cancer	4.27e-06	2.63e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MAPK3—breast cancer	4.25e-06	2.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MDM2—breast cancer	4.25e-06	2.62e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—KRAS—breast cancer	4.24e-06	2.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—MYC—breast cancer	4.24e-06	2.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RAF1—breast cancer	4.23e-06	2.61e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—TGFB1—breast cancer	4.23e-06	2.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—RELA—breast cancer	4.21e-06	2.6e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—ERBB2—breast cancer	4.19e-06	2.58e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—EGFR—breast cancer	4.14e-06	2.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR2—Signaling Pathways—AKT1—breast cancer	4.13e-06	2.55e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—MYC—breast cancer	4.13e-06	2.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MTOR—breast cancer	4.13e-06	2.54e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CB—breast cancer	4.13e-06	2.54e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TGFB1—breast cancer	4.12e-06	2.54e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—EGFR—breast cancer	4.04e-06	2.49e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CXCL8—breast cancer	3.97e-06	2.45e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—KRAS—breast cancer	3.91e-06	2.41e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—PIK3CA—breast cancer	3.89e-06	2.4e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1B—breast cancer	3.88e-06	2.39e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—KRAS—breast cancer	3.82e-06	2.35e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CASP3—breast cancer	3.8e-06	2.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL2—breast cancer	3.79e-06	2.34e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CCND1—breast cancer	3.7e-06	2.28e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—JUN—breast cancer	3.69e-06	2.27e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CTNNB1—breast cancer	3.66e-06	2.26e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—HRAS—breast cancer	3.6e-06	2.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—PIK3CA—breast cancer	3.6e-06	2.22e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MMP9—breast cancer	3.59e-06	2.21e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—CDKN1A—breast cancer	3.58e-06	2.2e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PTEN—breast cancer	3.57e-06	2.2e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—PIK3CA—breast cancer	3.51e-06	2.16e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK8—breast cancer	3.49e-06	2.15e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—IL6—breast cancer	3.45e-06	2.12e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—TP53—breast cancer	3.39e-06	2.09e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—HRAS—breast cancer	3.33e-06	2.05e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—SRC—breast cancer	3.31e-06	2.04e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—HRAS—breast cancer	3.25e-06	2e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—VEGFA—breast cancer	3.22e-06	1.99e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—STAT3—breast cancer	3.19e-06	1.97e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—IL6—breast cancer	3.18e-06	1.96e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Immune System—AKT1—breast cancer	3.18e-06	1.96e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—IL6—breast cancer	3.11e-06	1.91e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MAPK3—breast cancer	3.05e-06	1.88e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—PIK3CA—breast cancer	3.01e-06	1.86e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—MYC—breast cancer	2.97e-06	1.83e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TGFB1—breast cancer	2.96e-06	1.82e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Disease—AKT1—breast cancer	2.94e-06	1.81e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—EGFR—breast cancer	2.9e-06	1.79e-05	CbGpPWpGaD
Nedocromil—CYSLTR1—Signaling Pathways—AKT1—breast cancer	2.87e-06	1.77e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—KRAS—breast cancer	2.74e-06	1.69e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—PIK3CA—breast cancer	2.52e-06	1.55e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Metabolism—AKT1—breast cancer	2.46e-06	1.52e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—TP53—breast cancer	2.44e-06	1.5e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—HRAS—breast cancer	2.33e-06	1.44e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—IL6—breast cancer	2.23e-06	1.37e-05	CbGpPWpGaD
Nedocromil—HSP90AA1—Signaling Pathways—AKT1—breast cancer	2.06e-06	1.27e-05	CbGpPWpGaD
